ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
AstraZeneca
National Institutes of Health Clinical Center (CC)
Servier
AstraZeneca
Myeloid Therapeutics
Amgen
DualityBio Inc.
Boehringer Ingelheim
NextCure, Inc.
Tanabe Pharma America, Inc.
AstraZeneca
Bayer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bolt Biotherapeutics, Inc.
Institut Bergonié
Yuhan Corporation
Bristol-Myers Squibb
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Instituto do Cancer do Estado de São Paulo
Royal Marsden NHS Foundation Trust